| 摘要 |
This invention relates to novel substituted 1,4-benzodioxane compounds having antidiabetic, antihyperglycemic, and antiobesity properties represented by formula (II) wherein R<1> and R<6> are independently hydrogen, C1 to C6 alkyl, trifluoromethyl, cyano, C1 to C6 alkoxy, or halogen; R<2> is hydrogen or C1 to C6 trialkylsilyl; R<3> is hydrogen or C1 to C6 alkoxycarbonyl; or R<2> and R<3> are joined to form the oxazolidinone ring (III); R<4> and R<5> are independently hydrogen or C1 to C6 alkyl; R<7> and R<8> are independently OR<9> or NR<10>R<11>; R<9> is hydrogen, C1 to C12 alkyl, C1 to C12 cycloalkyl, C1 to C12 silylalkyl, phenyl, naphthyl, phenyl C<1> to C<6> alkyl, C1 to C6 alkoxy C1 to C6 alkyl, pyridyl, thiophenyl, furanyl, imidazolyl, oxazolyl, -CHR<12>COOR<13>, -CHR<12>C(O)R<13>, -CHR<12>CONR<10>R<11>, -CHR<12>OCOOR<13>, or -CHR<12>OC(O)R<13>; R<10> and R<11> are independently hydrogen, C1 to C12 alkyl, phenyl, naphthyl, phenyl-C1 to C6 alkyl, furanylalkyl, or alkoxycarbonylalkyl; R<12> and R<13> are independently hydrogen, C1 to C12 alkyl, phenyl, naphthyl, or phenyl-C1 to C6 alkyl; and the pharmaceutically acceptable salts thereof, a salt thereof; an enantiomer thereof, the racemic mixtures thereof, and the diastereomeric mixtures thereof. |
